CCA
ONC icon

Catalyst Capital Advisors’s BeOne Medicines Ltd ONC Stock Holding History

Catalyst Capital Advisors’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-85
Closed -$3K – 542
2016
Q2 		$3K Hold
85
– – ﹤0.01% 374
2016
Q1 		$2K Buy
+85
New +$2.41K ﹤0.01% 467

Other funds holding ONC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Catalyst Capital Advisors's ONC Position: Q3 2016 in Review

Catalyst Capital Advisors sold out of BeOne Medicines Ltd (ONC) in Q3 2016, closing a stake of 85 shares — an estimated $3K sold.

Catalyst Capital Advisors first reported a position in ONC in Q1 2016 and held it in 2 quarters. The position peaked at $3K in Q2 2016. 39 funds tracked by Wall St. Rank hold ONC as of Q3 2016.

  • Catalyst Capital Advisors reported no remaining BeOne Medicines Ltd position as of Q3 2016 after selling out during the quarter.
  • Catalyst Capital Advisors sold 85 BeOne Medicines Ltd shares in Q3 2016, an estimated $3K.
  • Catalyst Capital Advisors first reported a position in BeOne Medicines Ltd in Q1 2016 and held it in 2 quarters.
  • Catalyst Capital Advisors's BeOne Medicines Ltd position peaked at $3K in Q2 2016.
  • 39 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2016.

Based on Catalyst Capital Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.